VISEN PHARMA-B

2561
12.5600.80% ( +0.100 )
Delay Closed: Nov 16, 16:08:00

Overview

VISEN PHARMA-B (2561)

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese M...

Open
12.700
High
12.700
Low
11.510
Prev. Close
12.460
Volume
16.50K
Turnover
199.86K
Avg Price
12.113
Bid/Ask Ratio
-9.09%
Amplitude
9.55%
52wk High
43.300
Volume Ratio
1.72
Turnover Ratio
0.01%
52wk Low
10.900
HK Mkt Cap
1.43B
Market CapHKD
1.43B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-2.42
EPSDynamic
-2.11
EPSStatic
--
BVPS
6.79
P/B
1.85
HK Shares
113.75M
Dividend YieldTTM
--
DividendTTM
--
Shares
113.75M
Min lot size
100
Currency
HKD

VISEN PHARMA-B Analyst Rating

View more

Forecast & Rating

Sep 4, 2026
Price forecast
HK$49.99297.99%
Forecast & RatingBuy
1analysts
  • Strong buy0.00%
  • Buy100.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Visen Pharmaceuticals staged a morning-session rally before paring gains, touching an intraday high of HKD 26.96 and closing at HKD 26.42, up 5.68% from the previous close of HKD 25.00. The move was driven by multiple recent governance and commercial developments: the appointment of three new non-executive directors and continued share buyback and cancellation activities, signaling management's focus on value creation. While Q4 2025 net loss widened to HKD 75.3 million, the year-on-year loss contraction of 34.16% and an 88.32% improvement in EPS provided investors with marginal profit recovery signals. The stock remains 50.06% below its 52-week high of HKD 52.90 and beneath the MA60 of HKD 23.31, though it has reclaimed the MA20 (HKD 20.55) and rebounded roughly 40% from its 52-week low of HKD 18.88. However, the company is still in the pre-commercialization stage with persistent negative operating margins, and a fundamental turnaround in profitability remains unproven.

News